IGFBP5 and type 2 diabetes mellitus: In summary, the in vitro and in vivo experiments demonstrated that G9a inhibited the osteogenic potential of T2DM-BMSCs by regulating the LINC00657/miR-204-5p/IGFBP5 pathway.